Funds holding Lexeo Therapeutics Inc
ISIN US52886X1072 · United States
- Fund holders
- 133
- Of which ETFs
- 31 102 other funds
- Value held
- 80M $
- Share of capital
- 16.6 % of 82M shares on Aug 10, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VY(R) JPMORGAN SMALL CAP CORE EQUITY PORTFOLIO Voya Investors Trust | 3,726 | 21.4K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Invesco Russell 2000 Dynamic Multifactor ETF Invesco Exchange-Traded Self-Indexed Fund Trust | 3,575 | 25.7K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 3,370 | 24.2K $ | 0.03 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Small-Cap Equity Portfolio PACIFIC SELECT FUND | 3,011 | 17.3K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Russell 2000 High Income ETF ProShares Trust | 2,731 | 19.6K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Dimensional US Core Equity Market ETF Dimensional ETF Trust | 2,700 | 15.4K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| SA U.S. Small Company Fund SA FUNDS INVESTMENT TRUST | 2,615 | 15K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST | 2,513 | 14.4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| iShares Morningstar Small-Cap ETF iShares Trust | 2,491 | 14.2K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Small Company Value Portfolio Wilshire Mutual Funds Inc | 2,420 | 13.9K $ | 0.06 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SmallCap Value Fund II Principal Funds, Inc | 2,160 | 12.3K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Morgan Stanley Pathway Small-Mid Cap Equity ETF MORGAN STANLEY PATHWAY FUNDS | 2,153 | 15.5K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| EQ/Franklin Small Cap Value Managed Volatility Portfolio EQ Advisors Trust | 2,061 | 11.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Nationwide Fundamental All Cap Equity Portfolio Nationwide Mutual Funds | 2,003 | 11.4K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| U.S. VECTOR EQUITY PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 1,770 | 10.1K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Penn Series Small Cap Index Fund Penn Series Funds Inc | 1,700 | 9.8K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Dimensional US Vector Equity ETF Dimensional ETF Trust | 1,683 | 9.6K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| State Street Total Return V.I.S. Fund STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 1,571 | 9K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Destinations Small-Mid Cap Equity Fund Brinker Capital Destinations Trust | 1,487 | 10.7K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| SA Multi-Managed Small Cap Portfolio SEASONS SERIES TRUST | 1,250 | 7.2K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 1,210 | 6.9K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ULTRA SMALL CAP PROFUND ProFunds | 745 | 4.2K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 371 | 2.1K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 313 | 1.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 221 | 1.3K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 167 | 958.6 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 144 | 826.6 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 121 | 689.1 $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 86 | 493.6 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 65 | 466.7 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 62 | 355.9 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 19 | 136.4 $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 17 | 97.6 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.43 % | as of Apr 30, 2026 ↗ |
| Invesco Dorsey Wright SmallCap Momentum ETF Invesco Exchange-Traded Fund Trust II | 0.31 % | as of Feb 28, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.14 % | as of Mar 31, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 0.14 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund Goldman Sachs Variable Insurance Trust | 0.12 % | as of Mar 31, 2026 ↗ |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 0.12 % | as of Apr 30, 2026 ↗ |
| VANGUARD U.S. MOMENTUM FACTOR ETF VANGUARD WELLINGTON FUND | 0.11 % | as of Feb 28, 2026 ↗ |
| NVIT GS Small Cap Equity Insights Fund Nationwide Variable Insurance Trust | 0.11 % | as of Mar 31, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 0.10 % | as of Apr 30, 2026 ↗ |
| Goldman Sachs Small Cap Equity Insights Fund Goldman Sachs Trust | 0.09 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 133 | +13 | 13,610,155 | +13.5 % |
| 2026Q1 | 120 | +25 | 11,993,874 | +114.7 % |
| 2025Q4 | 95 | +18 | 5,585,199 | +20.9 % |
| 2025Q3 | 77 | -9 | 4,620,875 | +26.2 % |
| 2025Q2 | 86 | 0 | 3,660,462 | -25.5 % |
| 2025Q1 | 86 | +3 | 4,914,443 | +7.6 % |
| 2024Q4 | 83 | -7 | 4,565,282 | +9.3 % |
| 2024Q3 | 90 | +25 | 4,177,231 | +21.6 % |
| 2024Q2 | 65 | +57 | 3,435,546 | +23.6 % |
| 2024Q1 | 8 | 2,780,609 |
Institutional managers
133 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 6,184,134 | 35.5M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 5,110,871 | 29.3M $ | as of Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 5,050,211 | 29M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 5,000,000 | 28.7M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 4,976,429 | 28.5M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 4,475,000 | 25.7M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 4,424,725 | 25.4M $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 3,834,999 | 22M $ | as of Mar 31, 2026 |
| ORBIMED ADVISORS LLC | 3,602,450 | 20.7M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 3,568,242 | 20.5M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 2,750,532 | 15.8M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,949,885 | 11.2M $ | as of Mar 31, 2026 |
| Avoro Capital Advisors LLC | 1,875,000 | 10.8M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 1,680,449 | 9.6M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 1,612,780 | 9.3M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 1,589,585 | 9.1M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,513,777 | 8.7M $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 1,467,350 | 8.4M $ | as of Mar 31, 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,250,000 | 7.2M $ | as of Mar 31, 2026 |
| Nantahala Capital Management, LLC | 1,200,000 | 6.9M $ | as of Mar 31, 2026 |
| 683 Capital Management, LLC | 1,200,000 | 6.9M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,103,584 | 6.3M $ | as of Mar 31, 2026 |
| Octagon Capital Advisors LP | 1,100,000 | 6.3M $ | as of Mar 31, 2026 |
| Spruce Street Capital LP | 928,593 | 5.3M $ | as of Mar 31, 2026 |
| Blackstone Inc. | 904,959 | 5.2M $ | as of Mar 31, 2026 |
Declared shareholders of Lexeo Therapeutics Inc
There are 3 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Balyasny Asset Management L.P. and 4 others | 9.69 % | 7,176,144 | as of Mar 31, 2026 · SCHEDULE 13G |
| Paradigm BioCapital Advisors LP and 3 others | 8.30 % | 6,184,134 | as of Mar 31, 2026 · SCHEDULE 13G |
| SUVRETTA CAPITAL MANAGEMENT, LLC and 2 others | 7.70 % | 5,674,778 | as of Apr 6, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Lexeo Therapeutics Inc". https://titelia.com/en/stocks/lexeo-therapeutics-inc-US52886X1072